Ticagrelor: Oral Reversible P2Y 12 Receptor Antagonist for the Management of Acute Coronary Syndromes

Clinical Therapeutics

Volumn 34, Issue 6, 2012, Pages 1209-1220

  Cheng, Judy W M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet; Ticagrelor

Indexed keywords

2 OXO CLOPIDOGREAL; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARC 124910 XX; ARC 133913 XX; ATAZANAVIR; CARBAMAZEPINE; CLARITHROMYCIN; CLOPIDOGREL; DEXAMETHASONE; DIGOXIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NEFAZODONE; NELFINAVIR; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TELITHROMYCIN; TICAGRELOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPNEA; HAZARD RATIO; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MORTALITY; NON CORONARY ARTERY BYPASS GRAFT RELATED MAJOR BLEEDING; NON CORONARY ARTERY BYPASS GRAFT SURGERY RELATED MAJOR BLEEDING; PEER REVIEW; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACUTE CORONARY SYNDROME; ADENOSINE; ADMINISTRATION, ORAL; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84862134930     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.005     Document Type: Review

References (38)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart Disease and Stroke Statistics-2012 Update: A Report From the American Heart Association Accessed January 4, 2012. http://circ.ahajournals.org/content/early/2011/12/15/CIR.0b013e31823ac046.citation.
2. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1598-1660.
3. Davi G., Patrono C. Platelet activation and athero-thrombosis. N Engl J Med 2007, 357:2482-2494.
4. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Accessed January 5, 2012. http://circ.ahajournals.org/content/123/18/e426.full.pdf.
5. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (Updating the 2004 and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Accessed January 5, 2012. http://circ.ahajournals.org/content/120/22/2271.full.pdf.
6. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
7. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
8. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179-1189.
9. Pare G., Mehta S.R., Yusuf S., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010, 363:1704-1714.
10. Plosker G.L., Lyseng-Williamson K.A. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 2007, 67:613-646.
11. Wiviott S.D., Antman E.M., Braunwald E. Prasugrel. Circulation 2010, 122:394-403.
12. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetics, pharmacodynamic, and clinical outcomes. Circulation 2009, 119. 2553-2544.
13. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007, 357:2001-2015.
14. Brilinta (ticagrelor) tablets [prescribing information] Accessed January 5, 2012. http://www1.astrazeneca-us.com/pi/brilinta.pdf.
15. Capodanno D., Dharmashankar K., Angiolillo D.J. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010, 8:151-158.
16. Storey R.F. Pharmacology and clinical trials of reversibly binding P2Y12 inhibitors. Thromb Haemost 2011, 105(Suppl 1):S75-S81.
17. Plavix (clopidogrel bisulfate) tablets [prescribing information] Accessed March 15, 2012. http://products.sanofi.us/PLAVIX/PLAVIX.html.
18. Effient (prasugrel) tablets [prescribing information] Accessed March 15, 2012. http://pi.lilly.com/us/effient.pdf.
19. Teng R., Oliver S., Hayes M.A., Butler K. Absorption, distribution, metabolism and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010, 38:1514-1521.
20. Teng R., Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010, 66:487-496.
21. Butler K., Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010, 70:65-77.
22. Teng R., Mitchell P.D., Butler K. Lack of significant food effect on pharmacokinetics of ticagrelor in healthy volunteers Accessed January 5, 2012. http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2710.2011.01307.x/pdf.
23. Butler K., Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. J Clin Pharmacol 2011, 51:978-987.
24. Butler K., Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol Accessed January 5, 2012. http://jcp.sagepub.com/content/early/2011/09/29/0091270011415526.
25. Li H., Butler K., Yang L., et al. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single center study. Clin Drug Investig 2012, 32:87-97.
26. Gurbel P.A., Bliden K.P., Butler K., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010, 121:1188-1199.
27. Storey R., Angiolillo D.J., Patil S.B., et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet inhibitor and patient outcomes) PLATELET Substudy. J Am Coll Cardiol 2010, 56:1456-1462.
28. Wallentin L., Richard B.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
29. Cannon C.P., Harrington R.A., James S., et al. Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet 2010, 375:283-293.
30. James S.K., Row M.T., Cannon C.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized platelet inhibition and patient outcomes (PLATO) trial. BMJ 2011, 342:d3527.
31. Held C., Asenblad N., Bassand J.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011, 57:672-684.
32. Steg P.G., James S., Harrington R.A., et al. Ticagrelor versus clopidogrel in patients with ST elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 2010, 122:2131-2141.
33. James S., Budaj A., Aylward P., et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet inhibition and Patient Outcomes (PLATO) trial. Circulation 2010, 122:1056-1067.
34. James S., Angiolillo D.J., Cornel J.H., et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Eur Heart J 2010, 31:3006-3016.
35. Storey R.F., Becker R.C., Harrington R.A., et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and Platelet Outcome [PLATO] pulmonary function substudy). Am J Cardiol 2011, 108:1542-1546.
36. Scirica B.M., Cannon C.P., Emanuelsson H., et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol 2011, 57:1908-1916.
37. AstraZeneca Sets Premium Price for Ticagrelor (Brilinta) Accessed January 12, 2012. http://www.forbes.com/sites/larryhusten/2011/07/27/astrazeneca-sets-premium-price-for-ticagrelor-brilinta/.
38. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions Accessed January 12, 2012. http://circ.ahajournals.org/content/early/2011/11/07/CIR.0b013e31823ba622.